This company listing is no longer active
ELNJ Stock Overview
Elanix Biotechnologies AG, a tissue regeneration company, engages in the development and commercialization of products for acute wound care.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Elanix Biotechnologies AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.011 |
| 52 Week High | €0.08 |
| 52 Week Low | €0.001 |
| Beta | 0 |
| 1 Month Change | -65.00% |
| 3 Month Change | n/a |
| 1 Year Change | -79.00% |
| 3 Year Change | -97.38% |
| 5 Year Change | -99.60% |
| Change since IPO | -99.60% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| ELNJ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -5.1% | -2.0% |
| 1Y | -79.0% | -21.1% | -0.3% |
Return vs Industry: ELNJ underperformed the German Biotechs industry which returned -5.8% over the past year.
Return vs Market: ELNJ underperformed the German Market which returned 4% over the past year.
Price Volatility
| ELNJ volatility | |
|---|---|
| ELNJ Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ELNJ's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine ELNJ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Lee-Ann Laurent-Applegate | www.elanixbiotechnologies.ch |
Elanix Biotechnologies AG, a tissue regeneration company, engages in the development and commercialization of products for acute wound care. The company is based in Frankfurt am Main, Germany.
Elanix Biotechnologies AG Fundamentals Summary
| ELNJ fundamental statistics | |
|---|---|
| Market cap | €428.29k |
| Earnings (TTM) | -€4.46m |
| Revenue (TTM) | €280.19k |
0.0x
P/S Ratio0.0x
P/E RatioIs ELNJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELNJ income statement (TTM) | |
|---|---|
| Revenue | €280.19k |
| Cost of Revenue | €348.59k |
| Gross Profit | -€68.39k |
| Other Expenses | €4.39m |
| Earnings | -€4.46m |
Last Reported Earnings
Jun 30, 2018
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ELNJ perform over the long term?
See historical performance and comparison